D. E. Shaw & Co., Inc. Reata Pharmaceuticals Inc Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$79.22 - $105.37 $6.92 Million - $9.2 Million	-87,341 Reduced 93.5%	6,075 $619,000
Q1 2023 May 15, 2023	SELL	$30.85 - $93.17 $7.05 Million - $21.3 Million	-228,467 Reduced 70.98%	93,416 $8.49 Million
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $3.46 Million - $6.57 Million	156,053 Added 94.1%	321,883 $12.2 Million
Q3 2022 Nov 14, 2022	SELL	$19.41 - $36.49 $1.82 Million - $3.42 Million	-93,825 Reduced 36.13%	165,830 $4.17 Million
Q2 2022 Aug 15, 2022	BUY	$20.71 - $36.5 $4.22 Million - $7.44 Million	203,765 Added 364.58%	259,655 $7.89 Million
Q1 2022 May 16, 2022	BUY	$24.12 - $39.6 $187,195 - $307,335	7,761 Added 16.13%	55,890 $1.83 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $1.23 Million - $5.34 Million	48,129 New	48,129 $1.27 Million
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $583,611 - $1.06 Million	-5,720 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$93.53 - $163.34 $1.51 Million - $2.63 Million	-16,125 Reduced 73.82%	5,720 $557,000
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $2.41 Million - $3.37 Million	19,080 Added 690.05%	21,845 $3.41 Million
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $190,585 - $380,280	-1,535 Reduced 35.7%	2,765 $399,000
Q3 2019 Nov 14, 2019	SELL	$71.26 - $95.75 $1.43 Million - $1.92 Million	-20,029 Reduced 82.33%	4,300 $345,000
Q1 2019 May 15, 2019	BUY	$51.9 - $101.79 $266,402 - $522,488	5,133 Added 26.74%	24,329 $2.08 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $76.44 $1.31 Million - $2.05 Million	-26,823 Reduced 58.29%	19,196 $1.08 Million
Q3 2018 Nov 14, 2018	BUY	$35.64 - $92.06 $1.64 Million - $4.24 Million	46,019 New	46,019 $3.76 Million

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account